Stay updated on IL-15 Combo with Nivolumab & Ipilimumab in Refractory Cancers Clinical Trial
Sign up to get notified when there's something new on the IL-15 Combo with Nivolumab & Ipilimumab in Refractory Cancers Clinical Trial page.

Latest updates to the IL-15 Combo with Nivolumab & Ipilimumab in Refractory Cancers Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe date has been updated from January 10, 2025, to March 10, 2025.SummaryDifference0.3%
- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check44 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference6%
- Check51 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.3%
- Check65 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.3%
- Check73 days agoChange DetectedThe website has added a new version (v2.14.0) of the 'type of intervention' on January 10, 2025, while the previous version (v2.13.3) was removed on September 19, 2024.SummaryDifference2%
Stay in the know with updates to IL-15 Combo with Nivolumab & Ipilimumab in Refractory Cancers Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IL-15 Combo with Nivolumab & Ipilimumab in Refractory Cancers Clinical Trial page.